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Phosphodiesterase type 5 inhibitors such as sildenafil citrate and tadalafil are well
known for the treatment of erectile dysfunction. However, their use in the presence of
pulmonary hypertension can cause ophthalmologic side effects, including non-arteritic
optic ischemic neuropathy, chorioretinopathy, glaucoma, and optic atrophy. The present
review aimed to identify these visual side effects and provide recommendations. We
identified articles published from January 2000 to March 2019 on diseases arising
from the management of sexual dysfunction in urology or pulmonary hypertension in
pneumonia that could cause pathologic alterations in eye structure based on a literature
search of the MEDLINE electronic database using keywords for the most common
adverse effects and different kinds of phosphodiesterase 5 inhibitors. After applying the
exclusion criteria, we selected 36 of the 77 articles initially identified to write the narrative
review and added 20 additional articles to completely describe the pathological entities.
Phosphodiesterase type 5 inhibitors can cause side effects in the eye including
ocular surface abnormalities, increased intraocular pressure and glaucoma, uveitis,
non-arteritic ischemic neuropathy, chorioretinopathy, retinal occlusion, and visual field
changes. There is an increased need for well-performed studies to better understand
these side effects, which are common due to the wide use of sildenafil.
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INTRODUCTION
Erectile dysfunction (ED) is defined as a persistent
inability to achieve and/or maintain an erection
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to allow satisfactory sexual relations. It is a
prevalent condition, with over 18 million men
affected worldwide. ED affects an estimated 9.1%
of men aged 40–49 years, 15.2% of men aged
50–59 years, 29.4% of men aged 60–69 years,
and 54.9% of men older than 70 years.[1] The
first line of treatment for ED is phosphodiesterase
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type 5 inhibitors (PDE5i). This drug was first
developed to treat pulmonary hypertension and
muscle spasms; however, its most notable side
effect, prolonged erection, soon became the focus
of its use in clinical practice. In 1998, the Food
and Drug Administration (FDA) approved its use
as a clinically effective and safe treatment for
ED.[2]
There are 11 types of PDEs, all of which function
to degrade cyclic adenosine monophosphate
(AMPc) to adenosine monophosphate (AMP)
and GMPc to guanosine monophosphate
(GMP).[3] Sildenafil citrate (SC), a selective
inhibitor of PDE5i present in the cavernous
bodies in the penis, is responsible for smooth
muscle relaxation and, consequently, inducing
an erection.[1] PDE5i can cross the blood–
brain and blood–retinal barriers and may
partially inhibit the PDE 6 enzyme present in
the retina, with significant dose-dependent
changes in photoreceptors and the optical
nerve.[4–6] The main contraindication for the
use of PDE5i is its concomitant use with nitrates,
which can lead to hypotension and ischemic
events.[4]
The main reported side effects of PDE5i are
headaches, dizziness, blushing, nasal congestion,
dyspepsia, and visual changes. The most common
visual side effects are photophobia, cyanopsia, and
haze. Most of the visual effects can be reversed
weeks after stopping use of the medication.[3]
Other ophthalmologic disturbances described in
the literature include keratitis, ocular surface
abnormalities, chorioretinopathy, vessel occlusion,
retinal detachment, and optic neuropathy.[1, 4, 5, 7]
Considering the wide use of PDE5i, clinicians
should know its side effects profile. This study
reviewed the most common ocular effects related
to the use of PDE5i.
METHODS
A literature search was conducted through the
MEDLINE online electronic database for articles
written in English published from January 2000 to
March 2019. The reason to delimitate the research
to this period was to evaluate recent developments
regarding PDE5i and their side effects. Thus,
this review aimed to perform a current, but
thorough, analysis of published articles. We used
the following descriptors in sequence, all of
which had to be present in the title of the
article: (1) Keratitis OR (2) Surface Abnormalities
OR (3) Chorioretinopathy OR (4) Ocular OR (5)
Intraocular Pressure OR (6) Glaucoma OR (7) Non-
arteritic Anterior Ischemic Optic Neuropathy OR
(8) Retinal Occlusion OR (9) Optic Atrophy OR
(10) Visual Changes OR (11) Electroretinography
OR (12) Uveitis OR (13) Retinal AND (14) Sildenafil
AND (15) Phosphodiesterase 5 Inhibitors AND
(16) Tadalafil AND (17) Viagra AND (18) Vardenafil
AND (19) Avanafil AND (20) Udenafil AND (21)
Mirodenafil AND (22) Lodenafil AND 2000/01/01:
2019/03/31. The keywords from 1 to 13 were
searched again with AND 14 added; the same
process was performed to add keywords 15 to
22.
RESULTS
We selected 36 of the 77 articles initially identified
for the literature review, including both clinical
and experimental studies. We also included 20
additional articles to completely describe the
pathological entities [Figure 1]. We analyzed the
articles for the inclusion and exclusion criteria.
The inclusion criteria were articles that had
in their titles at least one combination of the
descriptors in the search strategy, publications
written in the English language, and relevant
content in the article regarding the research
topic. The exclusion criteria were articles that
had in the title or abstract nonophthalmic PDE
adverse effects related to PDE5i use; reviews and
book chapters; non-original studies including
editorials, exam alteration studies, preface
and brief communication; duplicate articles,
articles written in a language other than English;
and unavailable study abstract or full text. We
added two studies related to non-arteritic
anterior ischemic optic neuropathy (NAION)
since our search method identified few studies.
Furthermore, we also included 13 letters to editors
that described important side effects. We did not
find optic atrophy studies related to our topic;
similarly, no studies on mirodenafil, udenafil, or
lodenafil were identified. Each retrieved article
was carefully read and checked for relevance
before being included in the review [Figure
1].
We divided the visual side effects into the
following categories: keratitis, other surface
abnormalities, chorioretinopathy, intraocular
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Figure 1. Inclusion and exclusion criteria.
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Table 1. The best studies for each category
Finding Authors Concise Methods Brief Outcomes Strength of Evidence
Chart 1: Studies Related to Intraocular Pressure Alterations
Increased intraocular
pressure










Wirostko et al. 2012[15] -277 adults - Changes in
Intraocular Pressure
mean showed in 95%
confidence interval (CI)
-Grade B













Yajima et al. 2000[24] -Study 1with 16
subjects and study
2with 48 subjects
-No major changes - Grade B
Chart 2: Other Surface Abnormalities
Finding Authors Concise Methods Brief Outcomes Strength of Evidence
Surface abnormalities Matieli et al 2016[8] -Case control with
eyes in case group
and 13 eyes in control
group
-28 eyes (70%) using
sildenafil, while only 13




Finding Authors Concise Methods Brief Outcomes Strength of Evidence






Finding Authors Concise Methods Brief Outcomes Strength of Evidence
Central Serous
Chorioretinopathy
Turkuc et al 2013[11] -43 patients treated -Sildenafil citrate did





Finding Authors Concise Methods Brief Outcomes Strength of Evidence
Uveitis French et al[12] -Case report - 6 episodes of uveitis - Grade C
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Table 1. Continued.
Chart 6: Non-Arteritic Ischemic Optic Neuropathy
Finding Authors Concise Methods Brief Outcomes Strength of Evidence
Pomeranz et al[34] -Literature review - 40 case report
studies reported
- Grade C





NAION Gedik et al[37] -Case report - 36-year-old male who
presented blurry vision
in his left eye after 100
mg Sildenafil intake
- Grade C
Hafidi et al[38] - Case report - 40-year old man with
vision loss after 100
mg Sildenafil for two
consecutive days
- Grade C
Pomeranz et al[39] - Case series - 5 patients presented
after ingestion of 50 to
100 mg of Sildenafil
- Grade C





Chart 7: Retinal Vessel Occlusion




Tripathi et al[33] -Case report 69-year-old male who
presented with sudden
painless vision loss






Hafidi et al[38] -Case report -40-year-old male who
presented with acute
vision loss after 2 days
of Sildenafil 100 mg
intake
-Grade C














Chart 8: Visual Change
Finding Authors Concise Methods Brief Outcomes Strength of Evidence
-Color discrimination
alterations
Cordell et al[56] -Clinical trial - Any significant
evidence after
compared Sildenafil
intake for 6 months
daily
-Grade A
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pressure and glaucoma, uveitis, NAION, and
retinal occlusion. We described each category
in different sections; namely, epidemiology and
pathophysiology, clinical presentation, literature




In less developed countries, infectious keratitis
affects about 10% of the population. Eye injury
during agricultural work may predispose infectious
agents to cause keratitis. In developed countries,
the main cause of this condition is the use of
contact lenses.
Clinical presentation
Keratitis presents intense itching accompanied by
redness, pain, photophobia, red eye, and a “gritty”
sensation.[4]
Literature review
We did not find any association between PDE5i
use for ED and keratitis. However, a case–control
study that evaluated ocular toxicity in patients with
pulmonary arterial hypertension (PAH) reported
a higher incidence of keratitis following chronic
SC use. Twenty patients in each group were
administered SC from 1 to 60 months at daily doses
of 60 mg, except for two patients treated with 120
mg per day. One-third of PAH individuals using SC
had severe noninfectious bilateral keratitis. Such
patients were not contact lens users. A multivariate
analysis using a linear regression model showed
that dry eye keratitis was significantly associated
with SC use. The patients had no other risk factors
for dry eye, suggesting that SC use was possibly
the main cause of keratitis in these patients.[8]
Final statement recommendation
Patients who will start chronic PDE5i use and
have complaints of dry eye or who use contact
lenses should be counseled about an increased
risk of keratitis. Referral for routine ophthalmic
assessment and use of Preservative-free tear
substitutes should be considered.[8]
Other Surface Abnormalities
Epidemiology and pathophysiology
Dry eye disease (DED) is the most common
disorder related to surface abnormalities and has
been associated with a wide range of traits,
including systemic and metabolic conditions.
Clinical presentation
Dryness, burning, itching, watering, stickiness, and
crustiness.[9]
Literature review
Only one article was identified related to this
topic. In the same case–control study that
evaluated ocular toxicity in PAH patients using
SC, all participants presented ocular motility,
contrast sensitivity, color vision, Schirmer test,
intraocular pressure (IOP), and optical coherence
tomography (OCT) within the normal ranges. At
least one of these other abnormalities of the ocular
surface (tarsal gland dysfunction, conjunctival
hyperemia, cornea verticillata, and decreased
rupture time) were present in 28 eyes (70%) using
SC, compared to only 13 eyes (35%) in the control
group. Considering the presence of at least one
abnormality in biomicroscopy, SC users (40 eyes
of 20 patients) had a statistically higher occurrence
of anterior superficial anomalies (Fisher’s test p =
0.012).[8]
Final statement recommendation
Patients with PAH chronically treated with
SC should undergo routine ophthalmologic




Central serous chorioretinopathy (CSC) typically
affects men and women between their third and
sixth decades of life.[11] The major risk factors
are the state of refraction, systemic hypertension,
male sex, older age, black ethnicity, and use of
corticosteroids.[10]
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Clinical presentation
CSC presents as a painless dark, blurred, distorted,
dimmed area in the central vision.[11]
Literature review
Two articles on this topic found no association
between SC use and CSC. In a prospective study,
43 patients with a mean age of 49.1 years (range
28–67) were treated for ED with SC (50 mg
two to three times per week for one month).
The patients were evaluated in the first week
and at the end of treatment. Macular thickness
and volume assessments with OCT did not differ
significantly in the central and parafoveal areas
(p > 0.05). The study concluded that SC in
therapeutic doses did not lead to CSC and visual
abnormality.[11] French et al[12] studied 577 men
aged 59 years and younger with newly diagnosed
CSC. To avoid confounding factors, this study did
not include individuals with age-related macular
degeneration and history of corticosteroid use.
The authors found that 111 patients (19.2%) were
prescribed PDE5i before CSC onset, and most
(>99%) were administered SC doses of 100 mg or
more [odds ratio: 1.05, 95% confidence interval (CI):
0.74–1.22].[12] In contrast, Gordon-Bennett et al[13]
reported an inkblot appearance near the fovea
in a 51-year-old male patient 24 hr following the
ingestion of more than 20 mg tadalafil.
Final statement recommendation
Patients who are about to start ED treatment
with PDE5i should be advised to consult an
ophthalmologist in case they experience vision
problems.[11]
Intraocular Pressure and Glaucoma
Epidemiology and pathophysiology
The global prevalence of glaucoma was over 57
million individuals in 2015 and is expected to
increase to over 65 and 111 million individuals
by 2020 and 2040, respectively. Angle closure
and reduction of ocular blood flow are additional
mechanisms for the development of glaucoma,
which can be triggered by the systemic use of
vasodilators, including some PDE5i.[14–17]
Clinical presentation
In primary open-angle glaucoma, which is the
most common type of glaucoma, the patient is
usually oligosymptomatic and visual changes are
present only in advanced stages. In acute-angle
glaucoma, sudden visual pain followed by nausea
and vomiting is usually the initial presentation.[18]
Literature review
Nine articles discussed this topic. Some authors
reported increased IOP after SC use.[19] Nazari
et al[20] reported increased mean IOP after
three months in 110 patients aged 42–60
years with weekly SC doses of 25–100 mg (p
= 0.002).[20] Furthermore, Chen et al[21] evaluated
the prevalence of self-reported glaucoma in a
telephone-based interview in men aged over 40
years. They found that 482 of 7,081 participants
reported a diagnosis of glaucoma and the use of
SC in the previous year. However, the dose and
frequency of PDE5i intake were not investigated.[21]
Gerometta et al[22] studied nine healthy male and
female volunteers aged 18–74 years, in which the
IOP increased 60 min after SC administration (p <
0.005) and returned to the control values within
2 hr.[22] Gerometta et al[23] also demonstrated
increased IOP in 21 normal sheep after ingestion
of both SC (50 and 100 mg) and tadalafil. Other
research has shown no association between
SC use and IOP increase. Yajima et al[24] did not
detect anymajor changes in IOP 24 hr after the oral
administration of 10–150 mg SC I. Furthermore,
Wirostko et al[15] reported no changes in IOP
among 277 adults with idiopathic PAH in a double-
blind study using oral SC (20, 40 or 80 mg) or
placebo (1:1:1:1) three times daily for 12 weeks.[15]
Ermis et al[25] failed to show any significant effects
of SC use on IOP in 28 healthy volunteers with a
mean age of 51 years receiving SC (50 and 100
mg).[25] Moreover, in a double-blind, randomized,
placebo-controlled, crossover study, Grunwald
et al[16] reported no significant acute changes on
IOP after a single oral dose of SC l 100 mg in 15
subjects aged 63 ± 14 years with bilateral chronic
open-angle glaucoma.[16] Dündar et al[26] also
showed no change in IOP after the administration
of a single oral dose of 50 mg SC to 14 healthy
male volunteers tested immediately before and 1
hr after SC administration.[26]
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Final statement recommendation
There is a lack of prospective randomized trials
to determine whether there is a true causal
association between PDE5i use and elevation
of IOP leading to glaucoma development or
deterioration. However, it is advisable to monitor
IOP periodically in high-risk patients[20] [Table 1].
Uveitis
Epidemiology and pathophysiology
The prevalence of idiopathic uveitis is similar
in studies from different countries. Although the
understanding of the pathogenesis of uveitis
is evolving, approximately 24–55% of patients
with uveitis have idiopathic or undifferentiated
uveitis.[27]
Clinical presentation
Uveitis is an intraocular inflammation due to an
inflammation of the uvea presenting as redness
and swelling of the uvea.[28]
Literature review
Only one article discussed this topic. The
association of PDE5i and the onset of uveitis
is limited to one case report, which described a
38-year-old man diagnosed with Behçet’s disease
15 years prior and without any occurrence of uveitis
for the past 12 years. After starting SC for ED, he
developed recurrent posterior uveitis in his left
eye. The uveitis episode started after the second
or third dose of SC, with a total of six episodes.[29]
Final statement recommendation
Patients with ED who plan to start PDE5i should
be informed of the risk for ocular side effects.
If a recurrence of ocular symptoms is observed
concomitant to PDE5i intake, patients should be
informed to stop treatment.[29]
NAION
Epidemiology and pathophysiology
The annual incidence of NAION is 1 in 10,000
cases and affects men and women equally.
It is more common in Caucasians than in
African, American, and Hispanic descendants.
NAION is a multifactorial disorder[30] and is
believed to be related to vascular insufficiency
in the optic nerve head. The condition is also
associated with short posterior ciliary artery
dysfunction. However, the mechanisms related
to the vasculopathy and ischemia remain
unclear and there is no consensus regarding
the possible associations between NAION and
PDE5i.[31, 32]
Clinical presentation
The primary presentation includes acute, painless,
unilateral visual loss, which confers an increased
risk of contralateral vision loss. The condition may
worsen over hours or days, with optic disc edema
and an afferent pupillary defect. Altitudinal defects
are a more common presentation in the visual
field.[16, 33]
Literature review
In their literature review, Pomeranz et al[34]
described 40 case reports of NAION. Posterior
ischemic optic neuropathy was also related to
SC use in some letters to the editor.[30, 35] Galvez-
Ruiz et al[36] reported a series of 10 patients who
presented with NAION with routine exposure to
SC (>2–3 times per week) during the weeks and
months before the ocular ischemia. NAION was
diagnosed based on clinical presentations, fundus
features consistent with NAION, and exclusion
of other possible etiologies. Half of the patients
in the study had a primary episode of unilateral
ischemic optic neuropathy. Despite the initial
adverse event (first episode of NAION), all patients
continued to use the medication and developed
a second episode of NAION in the contralateral
eye. Only 1 of the 10 patients presented with
bilateral simultaneous NAION.[36] Another report
described a 36-year-old male patient presenting
with blurred vision in his left eye and afferent
pupillary defect after the ingestion of 100 mg of
SC. Funduscopy revealed hyperemia and edema
in the lower portion of the left optic disc.[37] Hafidi
et al[38] reported an acute unilateral visual loss in a
previously healthy 40-year-old man after ingestion
of 100 mg SC for two consecutive days before the
onset of this visual symptom. In this particular case,
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SC was associated with NAION and cilioretinal and
central retinal vein occlusion (CRVO).[38] Pomeranz
et al[39] (2002) reported on five patients ranging
in age from 42 to 69 years after SC ingestion.
They demonstrated the characteristic findings
of NAION, including altitudinal visual field loss
and associated optic disc and/or peripapillary
hemorrhages. Pomeranz et al[39] later reported
on seven patients aged 50–69 years who had
typical symptoms of NAION within 36 hr after
the ingestion of SC for ED.[37, 40] However, in a
cohort of 8,893 patients prescribed SC by their
primary care physicians in England between April
and June 1999, NAION was reported only in a
61-year-old patient who had other risk factors
for NAION; thus, it was not possible to confirm
any association between SC and NAION.[40, 41]
However, Peter et al[42] reported an NAION case
in a patient with no known vasculopathy risk
factors.
Final statement recommendation
A history of NAION should be an absolute
contraindication to PDE5i therapy[43] and patients
who are at higher risk for NAION (such as small cup-
to-disc ratio and systemic arterial hypertension)




Central retinal artery occlusion (CRAO) occurs
in an estimated 1 in 100,000 individuals in the
general population and accounts for 1 in 10,000
ophthalmological outpatient visits.[45] An embolism
is the most common cause of CRAO.[46]
Clinical presentation
CRAO appears as a sudden, catastrophic visual
loss.[46]
Literature review
Tripathi et al[33] reported a case of a 69-year-old
man presenting with a sudden painless loss of
vision in the left eye two days previously. Fundus
examination of the right eye was normal whereas
the left eye showed a supratemporal branch retinal
artery occlusion. As the patient did not have any
of the risk factors for arterial occlusion, a more
detailed history was sought. The patient indicated
that he had taken SC (100 mg) a few hours
before he experienced the loss of vision in his left
eye.[33] Murthy et al[47] reported a case of bilateral
concurrent CRAO in a 37-year-old female African–
American patient with sickle cell disease and PAH.
She had been treated with tadalafil (40 mg) once
daily for four weeks. Fluorescein angiography (FA)
revealed delayed transit time with areas of blocked
fluorescence due to retinal edema,[48] and spectral-
domain OCT revealed inner retinal edema in the
macula.[47] Hafidi et al[38] reported a case of CRAO
and CRVO observed by OCT and FA. The 40-
year-old male patient was previously healthy and
presented with acute visual loss of the left eye
after two days of 100 mg SC use.[47] Pinto et al[49]
reported a case of a 36-year-old man with chronic
renal failure who was diagnosed with CRVO by FA
after ingesting 100 mg SC.
Final statement recommendation
Acute and severe complaints should alert clinicians
to CRAO. Patients with increased risks for
thromboembolic events should be counseled
about CRAO. Despite the anecdotal cases, it is not




Most cases of visual changes after PDE5i are
believed to be dose dependent and lead to mild
alterations in the visual system. These alterations
lead to complaints of blue-tinged vision and
increased brightness perception.[51] SC also inhibits
phosphodiesterase type 6 (PDE6),[52] an essential
enzyme involved in the activation and modulation
of the phototransduction cascade, impairing the
ability of PDE6 to shorten the time of integration
between the visual system and light level.[53] The
sensitivity of SC for PDE6 isoenzymes is thought to
be the basis for the reduced electrophysiological
response on electroretinograms (ERG) in patients
prescribed 50 mg SC, as well as the transient color
vision abnormalities more likely to be observed
with higher doses of SC.[54]
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Clinical presentation
Patients report changes related to color
perception.[55]
Literature review
In a comparative case series study, Matieli et al[8]
analyzed the visual effects of SC use for PAH
by assessing symptoms such as bluish vision,
photophobia, and green or blue or yellow patterns
on Farnsworth D15-Color Test Saturated Panels.
SC was used from 1 to 60 months. The SC user
and control groups included 17 women each. One-
third of the treated group showed severe bilateral
keratitis. In contrast, Cordell et al[56] randomized
244 subjects to receive tadalafil (5mg, 85 patients),
SC (50 mg, 77 patients), or placebo (82 patients)
daily for six months. No significant differences
in the visual function of color discrimination by
the Farnsworth–Munsell 100-Hue Color Vision Test
were observed between the treatment and placebo
groups.[56]
Final statement recommendation
Despite its low occurrence, patients should
be counseled about transient color changes
associated with PDE5i use for ED or PAH.[8]
SUMMARY
PDE5i are one of the most prescribed drugs
worldwide, with a very good safety profile.
However, NAION, chorioretinopathy, and color
changes are important issues reported in the
literature. Although these visual side effects have
been reported in patients using PDE5i, there is not
enough evidence to prove a causal association.
Given the low incidence of such side effects,
these should not preclude the usual indications
for PDE5i. However, patients with histories of
ophthalmologic conditions or optic nerve issues
or those at high risk for any eye disease require
specific clearance before the commencement of
therapy.
Acknowledgement
The authors would like to thank Federal University
of Ceara and Christus University Center for
collaboration and Editage (www.editage.com) for
English language editing.
Financial Support and Sponsorship
Nil.
Conflicts of Interest
There is no conflict of interest.
REFERENCES
1. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors
for erectile dysfunction in the US.Am JMed 2007;120:151–
157.
2. Kehat R, Bonsall DJ, North R, Connors B. Ocular findings
of oral sildenafil use in term and near-term neonates. J
AAPOS 2010;14:159–162.
3. Sowka JW, Neiberg MN, Vollmer LA. Optic atrophy after
sildenafil use. Optometry 2007;78:122–128.
4. Hom MM, Nguyen AL, Bielory L. Allergic conjunctivitis
and dry eye syndrome. Ann Allergy Asthma Immunol
2012;108:163–166.
5. Keay L, Stapleton F, Schein O. Epidemiology of contact
lens-related inflammation and microbial keratitis: a 20-
year perspective. Eye Contact Lens 2007;33:346–353,
discussion 62–63.
6. Gupta N, Tandon R, Gupta SK, Sreenivas V, Vashist P.
Burden of corneal blindness in India. Indian J Community
Med 2013;38:198–206.
7. Nirmalan PK, Katz J, Tielsch JM, Robin AL, Thulasiraj RD,
Krishnadas R, et al. Ocular trauma in a rural south Indian
population: the Aravind Comprehensive Eye Survey.
Ophthalmology 2004;111:1778–1181.
8. Matieli L, Berezovsky A, Salomao SR, Allemann N, Martins
EN, Hirai FE, et al. Ocular toxicity assessment of chronic
sildenafil therapy for pulmonary arterial hypertension.
Graefes Arch Clin Exp Ophthalmol 2016;254:1167–1174.
9. The definition and classification of dry eye disease:
report of the Definition and Classification Subcommittee
of the International Dry Eye WorkShop (2007). Ocul Surf
2007;5:75–92.
10. Damar E, Toklu Y, Tuncel A, Balci M, Aslan Y, Simsek S,
et al. Does therapeutic dose of sildenafil citrate treatment
lead to central serous chorioretinopathy in patients with
erectile dysfunction? Am J Mens Health 2013;7:439–443.
11. Turkcu FM, Yuksel H, Sahin A, Murat M, Bozkurt Y, Caca
I. Central serous chorioretinopathy due to tadalafil use. Int
Ophthalmol 2013;33:177–180.
12. French DD, Margo CE. Central serous chorioretinopathy
and phosphodiesterase-5 inhibitors: a case-control
postmarketing surveillance study. Retina 2010;30:271–
274.
13. Gordon-Bennett P, Rimmer T. Central serous
chorioretinopathy following oral tadalafil. Eye
2012;26:168–169.
14. Kapetanakis VV, Chan MP, Foster PJ, Cook DG, Owen
CG, Rudnicka AR. Global variations and time trends in
the prevalence of primary open angle glaucoma (POAG):
a systematic review and meta-analysis. Br J Ophthalmol
2016;100:86–93.
JOURNAL OF OPHTHALMIC AND VISION RESEARCH VOLUME 16, ISSUE 2, APRIL-JUNE 2021 257
PDE5i and Ocular Side Effects; Barroso et al
15. Wirostko BM, Tressler C, Hwang LJ, Burgess G, Laties AM.
Ocular safety of sildenafil citrate when administered
chronically for pulmonary arterial hypertension:
results from phase III, randomised, double masked,
placebo controlled trial and open label extension. BMJ
2012;344:e554.
16. Grunwald JE, Jacob SS, Siu K, Piltz J, Dupont J. Acute
effects of sildenafil citrate (Viagra) on intraocular pressure
in open-angle glaucoma. Am J Ophthalmol 2001;132:872–
874.
17. Lee WJ, Seong M. Sildenafil citrate and choroidal
thickness. Retina 2011;31:1742; author reply -3.
18. Garg A, Gazzard G. Selective laser trabeculoplasty: past,
present, and future. Eye 2018;32:863–876.
19. Ramasamy B, Rowe F, Nayak H, Peckar C, Noonan
C. Acute angle-closure glaucoma following sildenafil
citrate-aided sexual intercourse. Acta Ophthalmol Scand
2007;85:229–230.
20. Nazari A, Tabrizi YT, Mokhtaree M. Effect of periodic
sildenafil dosage on intraocular pressure in patients with
erectile dysfunction. Electron Physician 2017;9:5229–
5232.
21. Chen SP, Singh K, Lin SC. Use of phosphodiesterase
inhibitors and prevalence of self-reported glaucoma in the
United States. PLoS ONE 2017;12:e0183388.
22. Gerometta R, Alvarez LJ, Candia OA. Effect of sildenafil
citrate on intraocular pressure and blood pressure in
human volunteers. Exp Eye Res 2011;93:103–107.
23. Gerometta R, Alvarez LJ, Candia OA. Effects of sildenafil
and tadalafil on intraocular pressure in sheep: implications
for aqueous humor dynamics. Invest Ophthalmol Vis Sci
2010;51:3139–3144.
24. Yajima T, Yajima Y, Koppiker N, Grunwald JE, Laties AM.
No clinically important effects on intraocular pressure after
short-term administration of sildenafil citrate (Viagra). Am
J Ophthalmol 2000;129:675–676.
25. Ermis SS, Inan UU, Samli M, Ozturk F. Acute effects
of sildenafil on Humphrey visual field and intraocular
pressure. Int Ophthalmol 2004;25:69–72.
26. Dundar SO, DundarM, Kocak I, Dayanir Y, Ozkan SB. Effect
of sildenafil on ocular haemodynamics. Eye 2001;15:507–
510.
27. Han YS, Rivera-Grana E, Salek S, Rosenbaum JT.
Distinguishing uveitis secondary to sarcoidosis
from idiopathic disease: cardiac implications. JAMA
Ophthalmol 2018;136:109–115.
28. Krishna U, Ajanaku D, Denniston AK, Gkika T. Uveitis: a
sight-threatening disease which can impact all systems.
Postgrad Med J 2017;93:766–773.
29. Isik M, Kilic L, Dogan I. Recurrent uveitis due to sildenafil
usage in a patient with Bechet’s disease. Rheumatol Int
2013;33:803.
30. Su DH, Ang PS, Tow SL. Bilateral posterior ischemic
optic neuropathy associated with use of sildenafil. J
Neuroophthalmol 2008;28:75.
31. Li A, Li L, Li M, Shi X. A new characterization for nonarteritic
anterior ischemic optic neuropathy. Int J Clin Exp Med
2015;8:18681–18688.
32. Boshier A, Pambakian N, Shakir SA. A case of nonarteritic
ischemic optic neuropathy (NAION) in a male patient
taking sildenafil. Int J Clin Pharmacol Ther 2002;40:422–
423.
33. Tripathi A, O’Donnell NP. Branch retinal artery occlusion;
another complication of sildenafil. Br J Ophthalmol
2000;84:934–935.
34. Pomeranz HD. Erectile dysfunction agents and nonarteritic
anterior ischemic optic neuropathy. Neurol Clin
2017;35:17–27.
35. Coca MN, Morgan ML, Gupta P, Elkeeb A, Lee AG.
Bilateral posterior ischemic optic neuropathy associated
with the use of Sildenafil for pulmonary hypertension. Can
J Ophthalmol 2016;51:e96–e99.
36. Galvez-Ruiz A, Arishi N. Sequential, non-arteritic anterior
ischemic optic neuropathy in patients taking sildenafil: a
report of ten cases. Saudi J Ophthalmol 2013;27:241–246.
37. Gedik S, Yilmaz G, Akova YA. Sildenafil-associated
consecutive nonarteritic anterior ischaemic optic
neuropathy, cilioretinal artery occlusion, and central
retinal vein occlusion in a haemodialysis patient. Eye
2007;21:129–130.
38. Hafidi Z, Handor H, Laghmari M, Daoudi R. Cilioretinal
artery and central retinal vein occlusion after sildenafil use.
Emerg Med J 2014;31:535.
39. Pomeranz HD, Smith KH, Hart WM Jr, Egan RA. Sildenafil-
associated nonarteritic anterior ischemic optic neuropathy.
Ophthalmology 2002;109:584–587.
40. Pomeranz HD, Bhavsar AR. Nonarteritic ischemic optic
neuropathy developing soon after use of sildenafil
(Viagra): a report of seven new cases. J Neuroophthalmol
2005;25:9–13.
41. Oguz H. Sildenafil-associated vascular casualties. Eye
2007;21:676–677; author reply 7–8.
42. Peter NM, Singh MV, Fox PD. Tadalafil-associated anterior
ischaemic optic neuropathy. Eye 2005;19:715–717.
43. Pepin S, Pitha-Rowe I. Stepwise decline in visual field after
serial sildenafil use. J Neuroophthalmol 2008;28:76–77.
44. Fraunfelder FW, Fraunfelder FT. Central serous
chorioretinopathy associated with sildenafil. Retina
2008;28:606–609.
45. Varma D, Lee AW, Chen CS. Reply: ’a review of
central retinal artery occlusion: clinical presentation and
management’. Eye 2014;28:1270.
46. Rudkin AK, Lee AW, Chen CS. Vascular risk factors for
central retinal artery occlusion. Eye 2010;24:678–681.
47. Murthy RK, Perez L, Priluck JC, Grover S, Chalam KV.
Acute, bilateral, concurrent central retinal artery occlusion
in sickle cell disease after use of tadalafil (Cialis). JAMA
Ophthalmol 2013;131:1471–1473.
48. Bertolucci A, Latkany RA, Gentile RC, Rosen RB. Hemi-
retinal artery occlusion associated with sexual activity
and sildenafil citrate (Viagra). Acta Ophthalmol Scand
2003;81:198–200.
49. Pinto LM, Morekar S, Mahashur AA. Central retinal vein
occlusion in a patient after being commenced on sildenafil
citrate for pulmonary arterial hypertension. Indian J Chest
Dis Allied Sci 2009;51:249–251.
50. Li AS, Pomeranz HD. Food and drug administration
adverse event reports of retinal vascular occlusions
associated with phosphodiesterase type 5 inhibitor use.
J Neuroophthalmol 2016;36:480–481.
51. Kinoshita J, Iwata N, Shimoda H, Kimotsuki T, Yasuda M.
258 JOURNAL OF OPHTHALMIC AND VISION RESEARCH VOLUME 16, ISSUE 2, APRIL-JUNE 2021
PDE5i and Ocular Side Effects; Barroso et al
Sildenafil-induced reversible impairment of rod and cone
phototransduction in monkeys. Invest Ophthalmol Vis Sci
2015;56:664–673.
52. Laties AM, Fraunfelder FT. Ocular safety of Viagra,
(sildenafil citrate). Trans Am Ophthalmol Soc 1999;97:115–
125; discussion 25–28.
53. Stockman A, Sharpe LT, Tufail A, Kell PD, Ripamonti C,
Jeffery G. The effect of sildenafil citrate (Viagra) on visual
sensitivity. J Vis 2007;7:4.
54. Farooq MU, Naravetla B, Moore PW, Majid A, Gupta R,
Kassab MY. Role of sildenafil in neurological disorders.
Clin Neuropharmacol 2008;31:353–362.
55. Sinha S, Pathak-Ray V, Ahluwalia H, Morgan JE. Viagra or
what? Eye 2004;18:446–448.
56. Cordell WH, Maturi RK, Costigan TM, Marmor MF, Weleber
RG, Coupland SG, et al. Retinal effects of 6 months
of daily use of tadalafil or sildenafil. Arch Ophthalmol
2009;127:367–373.
JOURNAL OF OPHTHALMIC AND VISION RESEARCH VOLUME 16, ISSUE 2, APRIL-JUNE 2021 259
